
Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's board fulfilled its fiduciary duties. Theravance maintains that the deal offers significant value, representing a premium over its stock price before the acquisition announcement.
STL.News
Original source

